European stock markets were broadly up on Friday afternoon. In Helsinki, the rise of the OMXH general index had faded to 0.2 percent from 0.3 percent at the opening. The index moved at 9,993 points, just below the ten-ton mark.
Vaihtokarje had told about a big company acquisition Nokia 1.1 percent up.
The company announced that it is buying a Californian manufacturer of optical network solutions and semiconductors Infineran for about 2.3 billion US dollars. Nokia will pay $6.65 per share for the company’s shares, which is 28 percent more than the stock’s closing price on Wednesday. The company strengthens Nokia’s market position in optical networks and clearly increases turnover from the United States.
Nokia’s goal is to obtain synergy benefits of 200 million euros from the deal in a comparable operating profit by 2027. The deal is estimated to improve Nokia’s comparable operating profit and earnings per share during the first year, and bring more than a ten percent improvement to comparable earnings per share in 2027.
Other most traded stocks Nordea was up 0.9 percent and Fortum 3.2 percent down. The other most traded ones were mostly on the rise.
Members of Fortum’s management team, general counsel Nora Steiner-Forsberg and Elisa’s the personnel and procurement director, who will become the personnel director and a member of the management team Evelina Dahl will leave Fortum at the end of 2024. Recruitment of followers will begin immediately.
Goldman Sachs lowered Fortum’s recommendation to sell from the previous hold. The company’s target price remained unchanged at 14.30 euros.
A health technology company was at the top of the stock market’s rise Nightingale 20 percent jump.
Nightingale entered into a partnership Boston Heartin with about selling Nightingale’s Health Check service in the United States. The goal of the parties is to start the pilot project in August 2024 at the latest.
Developer of biodegradable orthopedic implants Bioretec (+0.4%) said that the company’s Remeos trauma screw’s European CE mark marketing authorization application has been returned from the expert panel’s evaluation. The previously predicted schedule estimate was that the CE mark would be obtained by the end of the second quarter of 2024, but Bioretec now expects that it will be granted later than the previous schedule estimate.